Boosting anti-tumor immunity with an expanded neoepitope landscape.


Immune checkpoint blockade therapy has been successfully applied to many cancers, particularly tumors that harbor a high mutational burden and consequently express a high abundance of neoantigens. However, novel approaches are needed to improve the efficacy of immunotherapy for treating tumors that lack a high load of classical genetically-derived neoantigens. Recent discoveries of broad classes of non-genetically encoded and inducible neoepitopes open up new avenues for therapeutic development to enhance sensitivity to immunotherapies. In this review, we discuss recent work on neoantigen discovery, with an emphasis on novel classes of non-canonical neoepitopes.

More about this publication

Cancer research
  • Publication date 29-07-2022

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.